ALLAKOS INC.

Allakos Inc. is a clinical stage biopharmaceutical company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory and proliferative diseases. Its initial clinical focus is eosinophilic gastritis and/or eosinophilic duodenitis, inflammatory diseases of the gastrointestinal tract. The Company is focused on the development of lirentelimab (AK002) for the treatment of eosinophil and mast cell related diseases. The Company conducting clinical trials for other mast cell and eosinophil driven diseases including chronic urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis. Its lead compound, AK002, is in clinical development, and its other product candidates are in preclinical development. The Company’s operations are located in Redwood City, California.